Tango Therapeutics, Inc. (TNGX) Ownership
TNGX ownership summary
as of October 18, 2026- Institutions
- 128.7% of shares outstanding
- Insiders
- 1.19% of shares outstanding
- Shares outstanding
- 168.6M
- Float
- 120.7M shares available to trade
- Short interest
- 26.69% 44.5M shares short
- Days to cover
- 15.15 short interest up 6.3% vs prior month
- Institutions 128.75%
- Insiders 1.19%
TNGX top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | RTW INVESTMENTS, LLC | 8.24% | 13.9M | $306.4M | +600,000 (+4.5%) | June 30, 2026 |
| 2 | BlackRock Inc | 7.38% | 12.4M | $274.1M | +3.7M (+42.2%) | June 30, 2026 |
| 3 | FMR Inc | 7.31% | 12.3M | $271.8M | +2.4M (+24.5%) | June 30, 2026 |
| 4 | Farallon Capital Management, L.L.C. | 7.28% | 12.3M | $270.6M | +3.2M (+35.0%) | June 30, 2026 |
| 5 | Boxer Capital Management, LLC | 6.45% | 10.9M | $239.7M | — | June 30, 2026 |
| 6 | The Goldman Sachs Group Inc | 5.92% | 10.0M | $220.0M | +4.9M (+96.6%) | June 30, 2026 |
| 7 | TCG Crossover Management, LLC | 5.39% | 9.1M | $200.1M | −1.4M (−13.8%) | June 30, 2026 |
| 8 | TRV GP IV, LLC | 3.78% | 6.4M | $140.5M | — | June 30, 2026 |
| 9 | Paradigm Biocapital Advisors LP | 3.77% | 6.4M | $140.1M | +2.3M (+58.6%) | June 30, 2026 |
| 10 | T. Rowe Price Associates, Inc. | 3.77% | 6.3M | $139.9M | +5.5M (+613.8%) | June 30, 2026 |
| 11 | Siren, L.L.C. | 3.66% | 6.2M | $136.2M | +522,259 (+9.2%) | June 30, 2026 |
| 12 | State Street Corp | 3.55% | 6.0M | $131.8M | +1.3M (+28.5%) | June 30, 2026 |
| 13 | Vanguard Capital Management, LLC | 3.53% | 6.0M | $131.3M | +795,917 (+15.4%) | June 30, 2026 |
| 14 | Adage Capital Partners Gp LLC | 3.32% | 5.6M | $123.4M | −7.2M (−56.3%) | June 30, 2026 |
| 15 | Jupiter Topco LLC | 3.00% | 5.1M | $111.4M | +5.1M (0.0%) | June 30, 2026 |
| 16 | Deep Track Capital, LP | 2.49% | 4.2M | $92.6M | +1.4M (+52.7%) | June 30, 2026 |
| 17 | Deerfield Management Co | 2.49% | 4.2M | $92.4M | +43,798 (+1.1%) | June 30, 2026 |
| 18 | Woodline Partners LP | 2.37% | 4.0M | $88.2M | −4.0M (−50.0%) | June 30, 2026 |
| 19 | Geode Capital Management, LLC | 2.22% | 3.7M | $82.5M | +1.1M (+39.9%) | June 30, 2026 |
| 20 | Perceptive Advisors LLC | 2.00% | 3.4M | $74.4M | +2.6M (+317.9%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 15 holders added 35.4M shares and 3 cut 12.7M.
TNGX top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.61% | 4.4M | $97.1M | −5,262 (−0.1%) | August 31, 2026 |
| 2 | State Street® SPDR® S&P® Biotech ETF | 2.43% | 4.1M | $90.2M | −77,900 (−1.9%) | September 30, 2026 |
| 3 | iShares Russell 2000 ETF | 2.16% | 3.6M | $80.4M | −42,048 (−1.1%) | September 30, 2026 |
| 4 | Fidelity Growth Company Fund | 1.67% | 2.8M | $61.9M | +63,800 (+2.3%) | August 31, 2026 |
| 5 | Fidelity Select Biotechnology | 1.48% | 2.5M | $55.1M | +76,100 (+3.1%) | August 31, 2026 |
| 6 | Fidelity Small Cap Index | 0.91% | 1.5M | $33.9M | +12,850 (+0.8%) | July 31, 2026 |
| 7 | T. Rowe Price New Horizons | 0.84% | 1.4M | $31.0M | −57,531 (−3.9%) | August 31, 2026 |
| 8 | Polar Capital Biotech S Inc | 0.83% | 1.4M | $30.9M | — | August 31, 2026 |
| 9 | iShares Russell 2000 Growth ETF | 0.78% | 1.3M | $29.0M | −1,668 (−0.1%) | September 30, 2026 |
| 10 | T. Rowe Price Integrated US Sm Gr Eq | 0.71% | 1.2M | $26.5M | — | August 31, 2026 |
| 11 | iShares Biotechnology ETF | 0.64% | 1.1M | $24.0M | −8,240 (−0.8%) | September 30, 2026 |
| 12 | Franklin Biotechnology Discv A(acc)USD | 0.57% | 965K | $21.3M | — | August 31, 2026 |
| 13 | Lord Abbett Developing Growth A | 0.50% | 851K | $18.8M | +473,318 (+125.3%) | July 31, 2026 |
| 14 | Belfius Equities Cure C Cap | 0.49% | 823K | $18.1M | +165,030 (+25.1%) | March 31, 2026 |
| 15 | Vanguard Russell 2000 ETF | 0.48% | 810K | $17.8M | +19,168 (+2.4%) | August 31, 2026 |
| 16 | Janus Henderson Hrzn Biotec E2 USD | 0.48% | 808K | $17.8M | +407,391 (+101.6%) | June 30, 2026 |
| 17 | American Century Small Cap Growth Inv | 0.46% | 773K | $17.0M | +773,207 (0.0%) | June 30, 2026 |
| 18 | Schwab US Small-Cap ETF™ | 0.45% | 763K | $16.8M | +513 (+0.1%) | September 30, 2026 |
| 19 | Fidelity Series Growth Company | 0.45% | 750K | $16.5M | +13,600 (+1.8%) | August 31, 2026 |
| 20 | Fidelity Growth Company K6 | 0.44% | 735K | $16.2M | +36,000 (+5.1%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
TNGX insider transactions
latest 15| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-15 | Adam Crystal | Sell | $25.00 | 38,460 | $961,500 |
| 2026-04-01 | Adam Crystal | Sell | $21.20 | 27,000 | $572,400 |
| 2026-03-25 | Adam Crystal | Sell | $20.11 | 12,000 | $241,320 |
| 2026-03-05 | Adam Crystal | Sell | $15.00 | 20,251 | $303,765 |
| 2026-02-25 | Adam Crystal | Sell | $12.77 | 54,345 | $693,986 |
| 2026-02-03 | Adam Crystal | Sell | $12.26 | 18,452 | $226,222 |
| 2026-02-03 | Barbara Weber | Sell | $12.26 | 30,519 | $374,163 |
| 2026-02-03 | Daniella Beckman | Sell | $12.26 | 10,317 | $126,486 |
| 2025-10-23 | Rock Ventures Iv L.P. Third | Sell | $10.15 | 477,401 | $4.8M |
| 2025-09-25 | Rock Ventures Iv L.P. Third | Sell | $8.02 | 500,000 | $4.0M |
| 2025-09-16 | Rock Ventures Iv L.P. Third | Sell | $7.04 | 363,541 | $2.6M |
| 2025-09-08 | Rock Ventures Iv L.P. Third | Sell | $7.04 | 86,459 | $608,671 |
| 2025-09-05 | Rock Ventures Iv L.P. Third | Sell | $7.00 | 642,906 | $4.5M |
| 2025-08-22 | Rock Ventures Iv L.P. Third | Sell | $7.00 | 302,194 | $2.1M |
| 2025-08-19 | Rock Ventures Iv L.P. Third | Sell | $7.01 | 1,100,000 | $7.7M |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
TNGX shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns TNGX
Institutional investors own 128.7% of Tango Therapeutics's shares and insiders 1.19%. The largest holder is RTW INVESTMENTS, LLC with 8.24% of the shares (13.9M), as of June 30, 2026. Among the top 20 institutions, 15 added shares and 3 reduced their stake in the latest filings. Short interest is 26.69% of the float, or 15.15 days of average trading volume. The share count rose 32.8% since 2020.
Related: TNGX analyst forecast, TNGX key metrics. See the TNGX stock overview for the latest quote and news.
TNGX ownership FAQ
Who owns the most Tango Therapeutics stock?
The largest shareholders of Tango Therapeutics are RTW INVESTMENTS, LLC (8.24%), BlackRock Inc (7.38%), FMR Inc (7.31%), Farallon Capital Management, L.L.C. (7.28%), Boxer Capital Management, LLC (6.45%).
What percentage of Tango Therapeutics is owned by institutions?
Institutions hold 128.7% of Tango Therapeutics's shares outstanding; insiders hold 1.19%.
Which funds own Tango Therapeutics?
The largest fund holders of Tango Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (2.61%), State Street® SPDR® S&P® Biotech ETF (2.43%), iShares Russell 2000 ETF (2.16%), Fidelity Growth Company Fund (1.67%), Fidelity Select Biotechnology (1.48%).
What is Tango Therapeutics's short interest?
44.5M shares of Tango Therapeutics were sold short, 26.69% of the float; at the average daily volume it would take 15.15 days to cover.
Are insiders buying or selling Tango Therapeutics?
Of the latest 15 reported insider transactions in Tango Therapeutics (since August 19, 2025), 0 were purchases and 15 were sales.
How many shares of Tango Therapeutics are outstanding?
Tango Therapeutics has 168.6M shares outstanding, of which 120.7M are in the public float.